Enhancing the bioavailability of magnolol in rabbits using melting solid dispersion with polyvinylpyrrolidone

Drug Development and Industrial Pharmacy

Volumn 40, Issue 3, 2014, Pages 330-337

  Lin, Shiuan Pey ^a   Hou, Yu Chi ^a   Liao, Tzu Yun ^a   Tsai, Shang Yuan ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bioavailability enhancement; Dissolution rate; Magnolia officinalis; Pharmacokinetics; Solid dispersion; Sulfate glucuronide profiles

Indexed keywords

MAGNOLOL; POVIDONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; EXPERIMENTAL RABBIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MAGNOLIA OFFICINALIS; MAGNOLIACEAE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MELTING POINT; MELTING SOLID DISPERSION; NONHUMAN; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; LIGNANS; MALE; POVIDONE; RABBITS; SOLUBILITY;

EID: 84893962528     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.760580     Document Type: Article

References (24)

1. Ho JH, Hong CY. Cardiovascular protection of magnolol: cell-type specificity and dose-related effects. J Biomed Sci 2012;19:70.
2. Tsai YC, Cheng PY, Kung CW, et al. Beneficial effects of magnolol in a rodent model of endotoxin shock. Eur J Pharmacol 2010; 641:67-73.
3. Lee J, Jung E, Park J, et al. Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med 2005;71:338-43.
4. Lin YR, Chen HH, Ko CH, Chan MH. Effects of honokiol and magnolol on acute and inflammatory pain models in mice. Life Sci 2007;81:1071-8.
5. Nakazawa T, Yasuda T, Ohsawa K. Metabolites of orally administered Magnolia officinalis extract in rats and man and its antidepressant-like effects in mice. J Pharm Pharmacol 2003; 55:1583-91.
6. Yang SE, Hsieh MT, Tsai TH, Hsu SL. Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells. Br J Pharmacol 2003;138:193-201.
7. Lin SY, Liu JD, Chang HC, et al. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J Cell Biochem 2002;84: 532-44.
8. Nagase H, Ikeda K, Sakai Y. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro. Planta Med 2001;67:705-8.
9. Wang D, Jin Q, Xiang H, et al. Transcriptional and functional analysis of the effects of magnolol: inhibition of autolysis and biofilms in Staphylococcus aureus. PLoS One 2011;6:e26833.
10. Ho KY, Tsai CC, Chen CP, et al. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phytother Res 2001;15:139-41.
11. Tsai TH, Chou CJ, Lee TF, et al. Pharmacokinetic and pharmaco-dynamic studies of magnolol after oral administration in rats. Pharm Sci 1996;2:191-3.
12. Lin SP, Tsai SY, Lee Chao PD, et al. Pharmacokinetics, bioavailability, and tissue distribution of magnolol following single and repeated dosing of magnolol to rats. Planta Med 2011;77: 1800-5.
13. Lennernas H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol 2005;57:273-85.
14. Mallick S, Pattnaik S, Swain K, De PK. Current perspectives of solubilization: potential for improved bioavailability. Drug Dev Ind Pharm 2007;33:865-73.
15. Qian F, Huang J, Hussain MA. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci 2010;99: 2941-7.
16. Zheng W, Jain A, Papoutsakis D, et al. Selection of oral bioavailability enhancing formulations during drug discovery. Drug Dev Ind Pharm 2012;38:235-47.
17. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12:1068-75.
18. Serajuddin AT. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999;88:1058-66.
19. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47-60.
20. Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol 2009;61:1571-86.
21. Ning X, Sun J, Han X, et al. Strategies to improve dissolution and oral absorption of glimepiride tablets: solid dispersion versus micronization techniques. Drug Dev Ind Pharm 2011;37:727-36.
22. Karavas E, Ktistis G, Xenakis A, Georgarakis E. Miscibility behavior and formation mechanism of stabilized felodipine-polyvinylpyrrolidone amorphous solid dispersions. Drug Dev Ind Pharm 2005;31:473-89.
23. Tsai TH, Chou CJ, Chen CF. Glucuronidation of magnolol assessed using HPLC/fluorescence. Planta Med 1995;61:491-2.
24. Wang YJ, Chien YC, Wu CH, Liu DM. Magnolol-loaded core-shell hydrogel nanoparticles: drug release, intracellular uptake, and controlled cytotoxicity for the inhibition of migration of vascular smooth muscle cells. Mol Pharm 2011;8:2339-49.